OncoMatch/Clinical Trials/NCT06207734
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Is NCT06207734 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for breast cancer.
Treatment: Continuation of CDK4/6 inhibitor Palbociclib · Discontinuation of CDK4/6 inhibitor Palbociclib · Continuation of CDK4/6 inhibitor -Palbociclib · Discontinuation of CDK4/6 inhibitor -Palbociclib · Continuation of CDK4/6 inhibitor Abemaciclib · Discontinuation of CDK4/6 inhibitor Abemaciclib — This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (positive)
estrogen receptor positive (ER+)
Required: HER2 (ERBB2) wild-type (negative)
HER2 negative (HER2-)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: CDK4/6 inhibitor — plus endocrine therapy for at least 12 months with disease control
treated with CDK4/6 inhibitor plus endocrine therapy for at least 12 months with disease control (complete remission, partial remission or stable disease)
Lab requirements
Blood counts
hemoglobin > 9.0 g/dl; absolute neutrophil count judged as appropriate for study therapy by the investigator; platelets ≥ 100 x 10^9/l
Kidney function
calculated creatinine clearance judged as appropriate for study therapy by the investigator
Liver function
ast (sgot) / alt (sgpt) and alkaline phosphatase ≤ 2.5x uln; serum albumin > 30 g/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06207734 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received CDK4/6 inhibitor.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages